Callado L F, Martín-Gómez J I, Ruiz J, Garibi J M, Meana J J
Department of Pharmacology, University of the Basque Country, E-48940 Leioa, Spain.
J Neurol Neurosurg Psychiatry. 2004 May;75(5):785-7. doi: 10.1136/jnnp.2003.020446.
Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I(2) receptors are principally expressed on glial cells.
To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas.
The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from human gliomas of different grades.
The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed.
These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.
目前的胶质瘤分级方案受主观组织学标准限制。咪唑啉I(2)受体主要表达于神经胶质细胞。
探讨通过检测咪唑啉I(2)受体表达来区分胶质肿瘤与其他类型脑肿瘤以及对不同级别胶质瘤进行分级的可行性。
测定不同级别人类胶质瘤匀浆中[(3)H]伊达唑胺与咪唑啉I(2)受体的特异性结合。
三种恶性胶质肿瘤中咪唑啉I(2)受体的密度显著高于死后对照脑或非胶质肿瘤。密度增加与胶质瘤的恶性程度相关。亲和力值未观察到显著差异。
这些结果表明，咪唑啉I(2)受体的密度可能是用于区分胶质肿瘤与其他类型脑肿瘤以及对不同级别胶质瘤进行分级的有用放射性配体参数。
